 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910» |
- | Preclinical, Journal: In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. (Pubmed Central) - Aug 12, 2021
β-Lactam/BLI-BLE combinations were active in a higher proportion of INS-EC, INS-KP and INS-PA. The susceptibility of novel fluoroquinolones and tetracyclines was not superior to that of old ones.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Review, Journal: Approach to the treatment of patients with serious multidrug-resistant Pseudomonas aeruginosa infections. (Pubmed Central) - Aug 11, 2021
Though these newer agents are promising options for the treatment of MDR-PSA, clinical data remain generally limited. Future studies are needed to determine optimal agents for the empiric and definitive treatment of MDR-PSA.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Clinical, Journal: Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019. (Pubmed Central) - Jul 27, 2021
Among all ICU isolates, only 2.5% were nonsusceptible to both C/T and IMI/REL, while 6.7% were susceptible to C/T but not to IMI/REL and 3.5% were susceptible to IMI/REL but not to C/T. These data suggest that susceptibility to both C/T and IMI/REL should be considered for testing at hospitals, as both agents could provide important new options for treating patients with LRTIs, especially in ICUs where collected isolates show substantially reduced susceptibility to commonly used β-lactams.
- || QPX7728 / Qpex Biopharma, Brii Biosci
Review, Journal: QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics. (Pubmed Central) - Jul 23, 2021
QPX7728 can also be delivered orally; thus, its ultra-broad β-lactamase inhibition spectrum and other features could be also applied to oral QPX7728-based combination products. Clinical development of QPX7728 has been initiated.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring bla Isolated in New York City. (Pubmed Central) - Jul 21, 2021
Here, we report a novel bla variant (bla) and the complete genome sequence of bla-harboring K. pneumoniae strain BK13048, which is susceptible to carbapenems but resistant to ceftazidime-avibactam. To the best of our knowledge, this is one of the earliest KPC-producing K. pneumoniae strains exhibiting resistance to ceftazidime-avibactam.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Fetroja (cefiderocol) / Shionogi
Clinical, Journal: Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance. (Pubmed Central) - Jul 16, 2021
Our findings suggest that alterations in the target binding sites of P. aeruginosa-derived AmpC β-lactamases have the potential to reduce the activity of 3 of 4 novel β-lactams (ie, ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol) and potentially increase susceptibility to imipenem-relebactam. These findings are in need of validation in a larger cohort.
- | imipenem/relebactam / Merck (MSD)
Journal: Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales. (Pubmed Central) - Jul 11, 2021
Imipenem/relebactam, colistin and ceftazidime/avibactam were the most active antimicrobials against all CPEs. Imipenem/relebactam is a valuable addition to the antimicrobial arsenal used in the fight against CPE, particularly against KPC-producing isolates, which in all cases were susceptible to this combination.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Cross-border emergence of Escherichia coli producing the carbapenemase NDM-5 in Switzerland and Germany. (Pubmed Central) - Jul 10, 2021
The emergence of the NDM-5 carbapenemase was evidenced in particular for the E. coli ST167 clone, which is a successful epidemic clone, known to be associated to both multi-resistance and virulence traits and is therefore of high public health concern. The occurrence of clonally related NDM-5-producing E. coli isolates in Switzerland and Germany further indicates the international spread of this multidrug-resistant superbug at least throughout Europe.
- | rifampicin / Generic mfg.
Journal: Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. (Pubmed Central) - Jul 7, 2021
The occurrence of clonally related NDM-5-producing E. coli isolates in Switzerland and Germany further indicates the international spread of this multidrug-resistant superbug at least throughout Europe. MDR, absence of standard interpretation criteria and poor intermethod concordance necessitate working guidelines to facilitate future research of emerging Elizabethkingia spp.
- | Journal: Role of new antibiotics for KPC-producing Klebsiella pneumoniae. (Pubmed Central) - Jul 4, 2021
These modified agents from old antibiotic classes illustrate the challenges of this requirement to address class-specific resistance mechanisms while critical gaps and some cross-resistance within a class, or to unrelated antibiotic classes, remain. The diverse molecular mechanisms and increasing diversification of carbapenem resistance among Klebsiella isolates requires improved rapid molecular diagnostic capabilities and stringent stewardship programmes to preserve the efficacy of new antibiotics for as long as possible.
- || Review, Journal: Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections. (Pubmed Central) - Jul 4, 2021
Emerging treatment options for Gram-negative bacilli we considered comprise ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, aztreonam-avibactam, minocycline, fosfomycin, eravacycline, plazomicin, and cefiderocol...Knowledge of mechanisms of action and resistance patterns allows physicians to increasingly drive antimicrobial treatment towards a precision medicine approach. Strict adherence to antimicrobial stewardship practices will allow us to preserve the emerging antimicrobials for our future.
- | imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Journal: Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases. (Pubmed Central) - Jul 2, 2021
Relebactam did potentiate imipenem against ESBL-producing P. aeruginosa, which are mostly imipenem resistant via OprD loss, but this potentiation was generally insufficient to reduce imipenem MICs to the clinical range. Imipenem resistance owing to KPC carbapenemases was reversed by relebactam in P. aeruginosa, just as for Enterobacterales.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Preclinical, Journal: In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam against Clinical Isolates of Gram-Negative Bacilli with Difficult-to-Treat Resistance and Multidrug-Resistant Phenotypes - SMART United States 2015-2017. (Pubmed Central) - Jun 26, 2021
Imipenem/relebactam (Enterobacterales, P. aeruginosa) and ceftolozane/tazobactam (P. aeruginosa) retained in vitro activity against most DTR and MDR isolates.
- | relebactam (MK-7655) / Merck (MSD)
Preclinical, Journal, Combination therapy: In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against Pseudomonas aeruginosa in the murine thigh infection model. (Pubmed Central) - Jun 26, 2021
aeruginosa) retained in vitro activity against most DTR and MDR isolates. The imipenem/relebactam 500/250 mg q6h HSR demonstrated superior in vivo activity compared with the conventionally employed imipenem regimens against MDR P. aeruginosa over a wide range of imipenem/relebactam MICs.
- | imipenem/relebactam / Merck (MSD)
Preclinical, Journal: In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa. (Pubmed Central) - Jun 26, 2021
Imipenem/relebactam could be a useful alternative for the treatment of MDR P. aeruginosa infections, potentially reducing resistance development during treatment. Moreover, this work deciphers the potential resistance mechanisms that may emerge upon the introduction of this novel combination into clinical practice.
- | cefepime/zidebactam IV (WCK 5222) / Wockhardt
Journal: Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3. (Pubmed Central) - Jun 26, 2021
coli isolates concurrently harbouring four-amino-acid inserts in PBP3 and NDM are an emerging therapeutic challenge. Assisted by the PBP2-binding action of zidebactam, the cefepime/zidebactam combination overcomes both target modification (PBP3 insert)- and carbapenemase (NDM)-mediated resistance mechanisms in E. coli.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections. (Pubmed Central) - Jun 26, 2021
Assisted by the PBP2-binding action of zidebactam, the cefepime/zidebactam combination overcomes both target modification (PBP3 insert)- and carbapenemase (NDM)-mediated resistance mechanisms in E. coli. Modification of OXA-10 is a mechanism involved in the in vivo acquisition of resistance to cephalosporin/β-lactamase inhibitor combinations in P. aeruginosa.
- | imipenem/relebactam / Merck (MSD)
Preclinical, Journal: In vitro activity of imipenem-relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance United States 2015-2017. (Pubmed Central) - Jun 24, 2021
Modification of OXA-10 is a mechanism involved in the in vivo acquisition of resistance to cephalosporin/β-lactamase inhibitor combinations in P. aeruginosa. Imipenem-relebactam demonstrated potent in vitro activity against NPE and P. aeruginosa isolates from IAIs and UTIs, including against resistant subsets, and will provide important coverage for IAIs and UTIs caused by β-lactam-resistant, MDR, and KPC-positive Gram-negative bacilli.
- | imipenem/relebactam / Merck (MSD)
Journal: Imipenem-Relebactam Susceptibility Testing of Gram-Negative Bacilli by Agar Dilution, Disk Diffusion, and Gradient Strip Methods Compared with Broth Microdilution. (Pubmed Central) - Jun 24, 2021
Categorical agreement was 98.0% for agar dilution, 73.1% for disk diffusion, 96.3% for Etest, and 96.6% for MTS. In conclusion, agar dilution and Etest yielded comparable results to BMD for imipenem-relebactam.
- | QPX7728 / Qpex Biopharma, Brii Biosci
Preclinical, Journal: In Vitro Activity of the Ultra-Broad-Spectrum Beta-lactamase Inhibitor QPX7728 against Carbapenem-Resistant Enterobacterales (CRE) With Varying Intrinsic and Acquired Resistance Mechanisms. (Pubmed Central) - Jun 22, 2021
>90% of various CRE subsets (including those with reduced permeability) were susceptible to ≤8 μg/ml of meropenem with QPX7728 at 8 μg/ml or less. The combination of QPX7728 with meropenem against CRE has an attractive microbiological profile in CRE with multiple resistance mechanisms.
- | cefepime/zidebactam IV (WCK 5222) / Wockhardt
Preclinical, Journal: In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems. (Pubmed Central) - Jun 22, 2021
The activity of cefepime-zidebactam against carbapenem-resistant Gram-negatives is ascribed to its β-lactam enhancer mechanism of action (i.e., zidebactam binding to PBP2 and its universal stability to both serine β-lactamases and MBLs). The results from this study support the continued development of cefepime-zidebactam as a potential therapy for infections caused by Enterobacterales, P. aeruginosa, and other non-fermentative Gram-negative bacilli where resistance to marketed antimicrobial agents is a limiting factor.
- || imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Clinical, PK/PD data, Journal: A Single- and Multiple-Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. (Pubmed Central) - Jun 22, 2021
Relebactam/imipenem/cilastatin was well tolerated; mild adverse events occurred during single dosing, and one participant experienced serious adverse events after multiple doses. Pharmacokinetics and safety data are comparable with data from participants of other ethnicities, supporting the use of relebactam/imipenem/cilastatin at the approved dose and schedule in Chinese patients.
- || Clinical, PK/PD data, Journal: Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors. (Pubmed Central) - Jun 22, 2021
Suboptimal clinical response rate with ceftazidime-avibactam and ceftolozane-tazobactam was reported in phase II-III trials in patients with moderate kidney injury; data on patients undergoing renal replacement therapy are limited to some case reports; dose adjustment in augmented renal clearance is provided only for cefiderocol. Implementation of altered dosing strategies (prolonged infusion and/or higher dosage) coupled with adaptive real-time therapeutic drug monitoring could represent the most effective approach in warranting optimal pharmacokinetic/pharmacodynamic targets with novel BLs and/or BL/BLIs in challenging scenarios, thus minimizing the risk of clinical failure and/or of resistance selection.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
Preclinical, Journal: In vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-emergent Resistance to Ceftolozane-tazobactam. (Pubmed Central) - Jun 22, 2021
AmpC mutations were associated with cross-resistance to ceftazidime-avibactam, but increased susceptibility to piperacillin-tazobactam and imipenem. Eighty-one percent (12/16) of ceftolozane-tazobactam resistant isolates with ampC mutations were susceptible to imipenem-relebactam.
- | relebactam (MK-7655) / Merck (MSD)
Preclinical, Journal: Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab β-lactamase on the in vitro and intracellular efficacy of imipenem. (Pubmed Central) - Jun 10, 2021
Eighty-one percent (12/16) of ceftolozane-tazobactam resistant isolates with ampC mutations were susceptible to imipenem-relebactam. Inhibition of BlaMab by relebactam improves the efficacy of imipenem against M. abscessus in macrophages, indicating that the imipenem/relebactam combination should be clinically considered for the treatment of infections due to M. abscessus.
- imipenem/relebactam / Merck (MSD)
[VIRTUAL] Probability Of Simultaneously Providing Adequate Coverage Against K. Pneumoniae Carbapenemase (KPC)- Producing Enterobacterales And Multidrug-resistant P. Aeruginosa (MDR-PsA) In Hospitalized Patients: A Comparison Of Imipenem/relebactam With Other Antibiotics (SMART 2019, Global Data) (Poster Hall) - May 31, 2021 - Abstract #WMF2021WMF_4763;
In areas where KPC-E and MDR-PsA are endemic and antimicrobial therapy against pathogens is a routine part of clinical practice, imipenem/relebactam may be a useful option for clinicians in both empiric and directed antimicrobial regimens. Further studies are needed to define the clinical benefits that may translate from these findings and the specific settings where imipenem/relebactam is most favorable.
- | imipenem/relebactam / Merck (MSD)
Preclinical, Journal: Imipenem/Relebactam for Treatment of Carbapenem-Resistant Gram-negative Bacteria: Where Do We Stand on in vitro Susceptibility Testing? (Pubmed Central) - May 21, 2021
Further studies are needed to define the clinical benefits that may translate from these findings and the specific settings where imipenem/relebactam is most favorable. No abstract available
- imipenem/relebactam / Merck (MSD)
[VIRTUAL] In vitro activity of imipenem/relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa isolates from patients with respiratory tract infections in the Asia/Pacific region: SMART 2017-2019 () - May 20, 2021 - Abstract #ECCMID2021ECCMID_3891;
pneumoniae and P . aeruginosa were the two most common species in this collection of LRTI isolates from Asia/Pacific .
- imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Comparative study of the microbiological activity of imipenem/relebactam with respect to ceftazidime/avibactam against KPC-2 and KPC-3-producing Klebsiella pneumoniae: mutant preventive concentrations (MPC) and dynamics of appearance of resistance () - May 20, 2021 - Abstract #ECCMID2021ECCMID_2461;
- imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In vitro activity of imipenem/relebactam against KPC-producing Klebsiella pneumoniae isolates resistant to ceftazidime/avibactam and/or meropenem/vaborbactam () - May 20, 2021 - Abstract #ECCMID2021ECCMID_1985;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
[VIRTUAL] In vitro activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Pseudomonas aeruginosa and Enterobacterales collected from haematology and oncology patients in a nationwide study in Spain () - May 20, 2021 - Abstract #ECCMID2021ECCMID_1978;
- imipenem/relebactam / Merck (MSD)
[VIRTUAL] Compartive activity of imipenem/relebactam against Klebsiella pneumoniae KPC-3 producers () - May 20, 2021 - Abstract #ECCMID2021ECCMID_1924;
- [VIRTUAL] Comparative in vitro activity of ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and cefiderocol against Pseudomonas aeruginosa, including drug-resistant isolates at an academic medical center () - May 20, 2021 - Abstract #ECCMID2021ECCMID_1922;
- imipenem/relebactam / Merck (MSD)
[VIRTUAL] Antimicrobial susceptibility to imipenem and imipenem/relebactam among non-Morganellaceae Enterobacterales (NME) isolates encoding OXA-48-like enzymes collected globally from SMART 2017-2019 () - May 20, 2021 - Abstract #ECCMID2021ECCMID_1904;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
[VIRTUAL] Antimicrobial susceptibility to ceftolozane/tazobactam, imipenem/relebactam and comparators among Gram-negative isolates collected from patients in the Balkan region: SMART 2016-2019 () - May 20, 2021 - Abstract #ECCMID2021ECCMID_1903;
- Mycobutin (rifabutin) / Pfizer, Lupin, imipenem/relebactam / Merck (MSD)
[VIRTUAL] MDR Mycobacterium abscessus skin and soft tissue infection following autologous fat grafting in a cosmetic tourist to Kurdistan treated with an antibiotic combination including imipenem-relebactam and rifabutin () - May 20, 2021 - Abstract #ECCMID2021ECCMID_1769;
- imipenem/relebactam / Merck (MSD)
[VIRTUAL] Predicting the effects of imipenem/relebactam and doripenem/relebactam combinations against KPC-producing Klebsiella pneumoniae in time-kill experiments: MIC determined by traditional method versus using pharmacokinetically based concentration ratio () - May 20, 2021 - Abstract #ECCMID2021ECCMID_1654;
- |||| imipenem/relebactam / Merck (MSD)
So yes, it seems it was meropenem Resistant but Imipenem/Relebactam susceptible. Not the first time I see this. Any thoughts? @OncIDPharmd @ClancyNeil @cleverwebber @jobadd @davidvanduin @transplantID @JGPharmD @njrhodes_rx @IDPharmacometrx @a_lepak @jonathanhandMD @ABsteward (Twitter) - May 18, 2021
- imipenem/relebactam / Merck (MSD)
[VIRTUAL] In Vitro Activity of Imipenem-Relebactam Against Various Resistance Phenotypes/Genotypes of Enterobacterales and Pseudomonas aeruginosa Isolated from Patients Across Canada: CANWARD 2016-2020 (Poster Hall) - May 9, 2021 - Abstract #WMF2021WMF_2624;
Background: Imipenem-relebactam (IMI-REL) is FDA-approved for treating complicated urinary tract and complicated intra-abdominal infections, and hospital-acquired and ventilator-associated bacterial pneumonia. The in vitro activity (mg/L) and %S (susceptible) of IMI-REL, IMI, and piperacillin-tazobactam (PTZ) against selected Gram-negative bacilli is described in the table below.
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam, and Ceftazidime/Avibactam Against Resistant Pseudomonas aeruginosa: United States SMART 2017-2019 (Poster Hall) - May 9, 2021 - Abstract #WMF2021WMF_2618;
When C/T was not an option due to nonsusceptibility, I/R was the most active agent. Given the desirability of β-lactams among clinicians in treating serious infections, C/T and I/R represent important options in the treatment of infections caused by Pa.
- imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Phenotypic Assessment of Carbapenem and Carbapenem/β-lactamase Inhibitor Activity Against Oxa-48-producing Enterobacterales: The Challenge of Variable Hydrolysis and Definitive Breakpoints (Poster Hall) - May 9, 2021 - Abstract #WMF2021WMF_76;
Furthermore, differences in susceptibility breakpoints between MEM and MVB complicate enzyme detection utility. These data further indicate that precision medicine with genotypic testing may help optimize the use of the novel BLI combinations even when MICs are ‘susceptible’ in vitro.
- Fetroja (cefiderocol) / Shionogi
[VIRTUAL] Activity of cefiderocol and comparators against European isolates of Psuedomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, including carbapenem-resistant isolates () - May 8, 2021 - Abstract #ECCMID2021ECCMID_872;
The cefiderocol in vitro activity included PSA and ACB resistant subsets and SM, where treatment options are limited . These in vitro data suggest that cefiderocol is an important option for the treatment of infections caused by NGF, including resistant pathogens.
- | imipenem/relebactam / Merck (MSD)
Preclinical, Journal: In Vitro Activity of Imipenem/Relebactam Against Enterobacteriaceae Isolates Obtained from Intra-abdominal, Respiratory Tract, and Urinary Tract Infections in China: Study for Monitoring Antimicrobial Resistance Trends (SMART), 2015-2018. (Pubmed Central) - Apr 28, 2021
These in vitro data suggest that cefiderocol is an important option for the treatment of infections caused by NGF, including resistant pathogens. Given their high in vitro susceptibility, Enterobacteriaceae infections in China should be considered for IMI/REL treatment, especially with isolates that are not susceptible to carbapenems.
- | imipenem/relebactam / Merck (MSD)
Journal: Rapid detection of KPC-producing Enterobacterales by using a modified Carba NP test with imipenem/relebactam. (Pubmed Central) - Apr 22, 2021
Given their high in vitro susceptibility, Enterobacteriaceae infections in China should be considered for IMI/REL treatment, especially with isolates that are not susceptible to carbapenems. The biochemical assay provides very reliable results for detecting KPC-producing Enterobacterales, with a turnaround time of less than 1 hour, minimum handling and no specialized equipment required.
- | Preclinical, Journal: In vitro efficacy of Imipenem-Relebactam and Cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. (Pubmed Central) - Apr 20, 2021
The results lead to the proposal of alternative combination therapies involving REL and AAI to potentiate the use of β-lactams against clinical Gram-negative isolates expressing a variety of lactamases. They highlight the potential of novel combinations for combating strains not covered by existing therapies.
- || imipenem/relebactam / Merck (MSD)
I had encountered this scenario twice, and both times, cefepime failed me miserable, that is why I was skeptical, at least until the Port was out, I wanted to use imipenem-relebactam. It takes couple of days until Port comes out because very low (Twitter) - Apr 8, 2021
- | imipenem/relebactam / Merck (MSD)
Journal: Activity of imipenem/relebactam against carbapenem-resistant Escherichia coli isolates from the United States in relation to clonal background, resistance genes, co-resistance, and region. (Pubmed Central) - Apr 7, 2021
I/R remained substantially active against isolates co-resistant to comparator agents, albeit somewhat less so than against the corresponding susceptible isolates. These findings suggest that I/R should be useful for treating most CR E. coli infections in the U.S., largely independent of co-resistance, although this likely will vary in relation to the local prevalence of specific E. coli lineages and carbapenem resistance mechanisms.
- || Review, Journal: An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. (Pubmed Central) - Apr 7, 2021
All of these new antibiotics are active against ESBL, and almost all of them are active against CPE caused by KPC beta-lactamase, but only some of them are active against CPE due to MBL or OXA beta-lactamases. At present, all of these new antibiotics are approved by the U.S. Food and Drug Administration for cUTI (except eravacycline) and most of them for cIAI (eravacycline, ceftazidime/avibactam, ceftolozane/tazobactam, and imipenem/relebactam) and for HAP or VAP (cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, and imipenem/relebactam).
- || imipenem/relebactam / Merck (MSD)
Dear lord!!! Where is the Pseudomonas? High dose extended infusion imipenem relebactam plus amikacin. Mmm what else beside praying. Vancomycin-arginine and phage therapy (Twitter) - Mar 29, 2021
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, relebactam (MK-7655) / Merck (MSD)
Journal: Activity of imipenem-relebactam and meropenem-vaborbactam against carbapenem-resistant SME-producing Serratia marcescens. (Pubmed Central) - Feb 23, 2021
Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3/4, 0/4, and 4/4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.